A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi in adult patients
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Budesonide (Primary) ; Budesonide
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors PARI Pharma GmbH
- 24 Dec 2020 Status changed from recruiting to completed.
- 25 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 25 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 May 2019.